Telix Pharmaceuticals Limited TLPPF
8.95 USD 0.00 (+0.00%)
At closeNov 3, 2026, 4:00 PM EST
8.80 Day range 8.80
5.91 52-week range 13.00
- YTD
- +15.63%
- 1 year
- -12.17%
- Market cap
- 3.04B
- EPS (ttm)
- 0.10
- P/E ratio
- 89.50
- YTD return
- +15.63%
- 1-year return
- -12.17%
- Volume
- 400
- Avg volume
- 1.81K
- Open
- 8.80
- Previous close
- 8.95
- Day's range
- 8.80 – 8.80
- 52-week range
- 5.91 – 13.00
- Earnings date
- Aug 20, 2026
2Y -5.57 (-38.36%)
Next earnings
Aug 20, 2026
Expected Aug 20, 2026. Consensus EPS estimate 0.04336.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 20, 2026 | Jun 30, 2026 | 0.04336 | — | — | — |
| Feb 19, 2026 | Dec 31, 2025 | 0.03277 | -0.0116 | -0.04 | -135.40% |
| Aug 20, 2025 | Jun 30, 2025 | 0.1335 | -0.00677 | -0.14 | -105.07% |
| Feb 20, 2025 | Dec 31, 2024 | 0.09047 | 0.06856 | -0.02 | -24.22% |
| Aug 22, 2024 | Jun 30, 2024 | 0.09011 | 0.0222 | -0.07 | -75.36% |
| May 21, 2024 | Dec 31, 2023 | — | 0.04107 | — | — |
News
Australia's Telix Pharma agrees to buy Germany's ITM Isotope for about $1.65 billion 
Telix Seeks Reset With FDA Filing While Sales Growth Holds Steady 
Telix Pharmaceuticals: Solid Q1 As Pipeline And PSMA Franchise Drive Outlook 
Why Is Telix Pharma Stock Soaring Tuesday? 
Telix Pharmaceuticals (OTCMKTS:TLPPF) Shares Down 5.3% – Time to Sell? 
Telix Pharmaceuticals Limited (TLX) Discusses Revenue Growth, Prostate Cancer Imaging Portfolio, and Expansion into Brain and Kidney Cancer Transcript 
Telix Pharmaceuticals Limited (TLX) Discusses ProstACT Global Phase 3 Study Part 1 Results and Safety Profile Transcript 
Telix Pharmaceuticals Limited (TLX) Discusses Physician Perspectives on Innovations in PSMA PET CT Imaging for Prostate Cancer Transcript 
Telix Pharmaceuticals: Scope Of Company Beyond Radio Antibody-Drug Conjugate TLX591-Tx 
Telix Pharmaceuticals Limited (TLX) Q4 2025 Earnings Call Transcript
Your note
Sign in to keep a note on TLPPF — it syncs with the Stock Master app.